Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Etanercept in Pediatric Plaque Psoriasis
2012-001186-33Phase 3
- Sponsor
- Amgen
- Start
- Mar 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etanercept in plaque psoriasis and psoriasis, sponsored by Amgen. Primary endpoint: Safety - Adverse Events.
02
Drugs
etanercept
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2012-001186-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001186-33.